Virios Therapeutics, Inc. (VIRI): Price and Financial Metrics
GET POWR RATINGS... FREE!
VIRI Stock Price Chart Interactive Chart >
VIRI Price/Volume Stats
| Current price | $0.31 | 52-week high | $9.11 |
| Prev. close | $0.32 | 52-week low | $0.22 |
| Day low | $0.29 | Volume | 306,205 |
| Day high | $0.32 | Avg. volume | 443,895 |
| 50-day MA | $0.28 | Dividend yield | N/A |
| 200-day MA | $3.01 | Market Cap | 2.57M |
Virios Therapeutics, Inc. (VIRI) Company Bio
Virios Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of antiviral therapies to treat diseases associated with a viral triggered abnormal immune response including fibromyalgia. It offers IMC-1 a novel, proprietary, fixed dose combination of famciclovir and celecoxib. The company was founded by William L. Pridgen on February 28, 2012 and is headquartered in Alpharetta, GA.
Latest VIRI News From Around the Web
Below are the latest news stories about VIRIOS THERAPEUTICS INC that investors may wish to consider to help them evaluate VIRI as an investment opportunity.
Stock Pitch World Cup(TM), Educational Panels and 49 Companies to Present at the Planet MicroCap Showcase: VIRTUAL on December 6-8, 2022The Planet MicroCap Showcase: VIRTUAL taking place on December 6-8, 2022, where 49 MicroCap public companies will be presenting virtually. |
Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap ShowcaseATLANTA, November 29, 2022--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, today announced that Greg Duncan, Chairman and CEO of Virios Therapeutics will be attending and presenting at the Planet MicroCap Showcase, which is taking place virtually December 6 – 8, 2022. |
VIRI: Ready to Approach FDA with Phase 3 Plans…By David Bautz, PhD NASDAQ:VIRI READ THE FULL VIRI RESEARCH REPORT Business Update Post-Hoc Analysis of Phase 2b FORTRESS Trial Shows Naïve Patients Responded to IMC-1 Treatment In September, 2022, Virios Therapeutics, Inc. (NASDAQ:VIRI) announced topline results for the Phase 2b FORTRESS (Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of Herpes Simplex Virus-1) trial of |
H.C. Wainwright Remains a Hold on Virios Therapeutics (VIRI)H.C. Wainwright analyst Sean Lee CFA maintained a Hold rating on Virios Therapeutics (VIRI - Research Report) today. The company's shares closed yesterday at $0.32.According to TipRanks, Lee CFA is an analyst with an average return of -18.8% and a 26.36% success rate. Lee CFA covers the Healthcare sector, focusing on stocks such as Gritstone Oncology, Plus Therapeutics, and CASI Pharmaceuticals.The word on The Street in general, suggests a Hold analyst consensus rating for Virios Therapeutics.See the top stocks recommended by analysts >>Based on Virios Therapeutics' latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $3.67 million. |
Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate UpdateATLANTA, November 14, 2022--Virios Therapeutics, Inc. (Nasdaq: VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia ("FM"), today announced financial results for the third quarter ended September 30, 2022, as well as plans to advance development of its lead antiviral development candidate, IMC-1, as a potential new treatment for FM patients. |
VIRI Price Returns
| 1-mo | 31.36% |
| 3-mo | 3.51% |
| 6-mo | -95.57% |
| 1-year | -95.16% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 31.36% |
| 2022 | -95.39% |
| 2021 | -31.89% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...